Miv Therapeutics, Inc. (IVT) Tops Q4 EPS by 5c; offers guidance

Miv Therapeutics, Inc. (NYSE: IVT) reported Q4 EPS of $0.03, $0.05 better than the analyst estimate of ($0.02).

GUIDANCE:

Miv Therapeutics, Inc. sees FY2026 EPS of $0.16-$0.22, versus the consensus of $0.25.

For earnings history and earnings-related data on Miv Therapeutics, Inc. (IVT) click here.

You May Also Be Interested In

• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• New Mexico gas pipeline for Oracle data center delayed to 2027
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c